Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

The echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene represents a molecular target in a small subset of non-small cell lung cancers (NSCLCs). This fusion leads to constitutive ALK activation with potent transforming activity. In a pivotal phase...

Full description

Bibliographic Details
Main Authors: Katayama, Ryohei (Author), Benes, Cyril H. (Author), Lifshits, Eugene (Author), Ebi, Hiromichi (Author), Rivera, Victor M. (Author), Shakespeare, William C. (Author), Iafrate, A. John (Author), Engelman, Jeffrey A. (Author), Shaw, Alice (Contributor)
Other Authors: Koch Institute for Integrative Cancer Research at MIT (Contributor)
Format: Article
Language:English
Published: National Academy of Sciences, 2011-12-02T19:46:27Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items